Designer Drugs: Hearing Before the Subcommittee on Crime of the Committee on the Judiciary, House of Representatives, Ninety-ninth Congress, First Session, on H.R. 2014, H.R. 2977, H.R. 3936, and S. 1437, May 1, 1986U.S. Government Printing Office, 1986 - 199 sider |
Inni boken
Resultat 1-5 av 27
Side 15
... regulation , or alternative methods to control the diversion of legitimate precursor and essential chemicals to the illegal production of drugs of abuse . The Attorney General would be required to report all findings of such study to ...
... regulation , or alternative methods to control the diversion of legitimate precursor and essential chemicals to the illegal production of drugs of abuse . The Attorney General would be required to report all findings of such study to ...
Side 33
... regulatory efforts to control the distribution of illicit , addictive drugs of abuse like controlled substance analogs . This makes sense , for FDA is not equipped to conduct the types of investigations of illicit drugs and other ...
... regulatory efforts to control the distribution of illicit , addictive drugs of abuse like controlled substance analogs . This makes sense , for FDA is not equipped to conduct the types of investigations of illicit drugs and other ...
Side 60
... regulations in this type of investigation ? Dr. Tocus . There is no exemption . FDA's new drug testing proce- dures apply irrespective of the size of the organization or individ- ual developing a drug for human use . Mr. LUNGREN . So ...
... regulations in this type of investigation ? Dr. Tocus . There is no exemption . FDA's new drug testing proce- dures apply irrespective of the size of the organization or individ- ual developing a drug for human use . Mr. LUNGREN . So ...
Side 61
... regulations , that is , as I explained , it is not mar- keted , does not have an approved NDA , it is entering interstate commerce , and it has no IND , there is no exemption . The require- ments are uniform . Dr. Houk . Mr. Lungren ...
... regulations , that is , as I explained , it is not mar- keted , does not have an approved NDA , it is entering interstate commerce , and it has no IND , there is no exemption . The require- ments are uniform . Dr. Houk . Mr. Lungren ...
Side 87
... regulatory burdens that researchers must meet , which are not overwhelming but are more difficult to comply with than for non- controlled substances . But these manufacturers have other concerns . One representa- tive testified to the ...
... regulatory burdens that researchers must meet , which are not overwhelming but are more difficult to comply with than for non- controlled substances . But these manufacturers have other concerns . One representa- tive testified to the ...
Andre utgaver - Vis alle
Vanlige uttrykk og setninger
amended amphetamine appropriate approval Attorney bill California Chairman chemical structure chemists clandestine laboratories Committee compounds conducted Congress controlled substance analogs Controlled Substances Act Cosmetic Act criminal Department of Health designer drug manufacture designer drug problem drug abuse Drug Enforcement Drug Enforcement Administration drug or substance effect emergency scheduling exemption Federal Food fentanyl analogs fetus Florida Food and Drug GRINSPOON HAWKS Health and Human heroin HUGHES human consumption Human Services human subjects illegal illicit drug individuals informed consent Institutional Review Board intended for human intent to distribute investigational law enforcement legislation legitimate research LUNGREN MCCOLLUM MDMA meperidine MPPP MPTP NIDA paragraph Parkinson's disease potential procedures produce programs psychoactive drugs public health regulations research involving scientific Secretary of Health Senator CHILES specific statement studies subpart substance in Schedules substantially similar synthetic Thank therapeutic tion Tocus toxicity trolled substance